MedTrace Logo

Study to Determine Interaction Between the Use of Feminizing Hormone Therapy and Antiretroviral Agents Concomitantly Among Transgender Women

NCT03620734 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 40

Last updated 2019-10-09

No results posted yet for this study

Summary

Objective

1. To determine pharmacokinetic (PK) DDI between GAHT and ARVs used as PrEP and ART among TGW
2. To evaluate ARV adherence among TGW

Conditions

  • PrEP and ART

Sponsors & Collaborators

  • Thai Red Cross AIDS Research Centre

    lead OTHER

Principal Investigators

  • Nittaya Phanuphak, MD, PhD · Thai Red Cross AIDS Research Centre (TRCARC)

Eligibility

Min Age
18 Years
Max Age
40 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2017-11-30
Primary Completion
2019-10-01
Completion
2019-10-01

Countries

  • Thailand

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620734 on ClinicalTrials.gov